Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.

European archives of psychiatry and clinical neuroscience - 1 Feb 2013

Giegling Ina, Balzarro Beatrice, Porcelli Stefano, Schäfer Martin, Hartmann Annette M, Friedl Marion, Konte Bettina, Krämer Philipp, Möller Hans-Jürgen, De Ronchi Diana, Stassen Hans H, Serretti Alessandro, Rujescu Dan

Abstract excerpt

The present study explores whether ankyrin repeat and kinase domain containing 1 (ANKK1) and dopamine receptor D2 (DRD2) variants could predict efficacy and tolerability of haloperidol in the treatment of psychotic patients. We also attempted to replicate findings in a group of schizophrenic patients from the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) study. Eighty-eight acutely psychotic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analysis of Variance
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Haloperidol

Share to Pharmacogenetics

Share to Psychiatric Status Rating Scales

Share to Receptors, Dopamine D2

Share to Schizophrenia

Source

Identifiers

PMID: 22893251
DOI: 10.1007/s00406-012-0348-1

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.PMID 22893251Read ↗

Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.Semantic proximity Read ↗

The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.Semantic proximity Read ↗

Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia.Semantic proximity Read ↗

Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.Semantic proximity Read ↗

Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.Semantic proximity Read ↗

No influence of FAT polymorphisms in response to aripiprazole.Semantic proximity Read ↗

No influence of DTNBP1 polymorphisms on the response to aripiprazole.Semantic proximity Read ↗

Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.Semantic proximity Read ↗

DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia.Semantic proximity Read ↗

DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.Semantic proximity Read ↗

Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach.Semantic proximity Read ↗

AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.